Halozyme Therapeutics (NASDAQ:HALO) Trading 5.9% Higher

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s stock price rose 5.9% during trading on Wednesday . The company traded as high as $44.79 and last traded at $43.63. Approximately 653,201 shares changed hands during mid-day trading, a decline of 46% from the average daily volume of 1,200,106 shares. The stock had previously closed at $41.21.

Analysts Set New Price Targets

Several analysts have issued reports on the company. StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. Benchmark reiterated a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday. JMP Securities dropped their price objective on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research note on Wednesday. Finally, The Goldman Sachs Group decreased their target price on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, January 18th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $53.14.

Halozyme Therapeutics Trading Down 0.1 %

The firm has a 50-day moving average of $40.17 and a 200 day moving average of $38.05. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. The stock has a market capitalization of $5.56 billion, a price-to-earnings ratio of 20.78, a PEG ratio of 0.47 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 3.43 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total transaction of $416,400.00. Following the transaction, the senior vice president now owns 156,558 shares in the company, valued at $6,519,075.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders sold 30,000 shares of company stock valued at $1,196,800. Company insiders own 2.70% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Rise Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at $25,000. Whittier Trust Co. acquired a new stake in shares of Halozyme Therapeutics during the first quarter worth $27,000. Principal Securities Inc. purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at $34,000. Fidelis Capital Partners LLC acquired a new position in shares of Halozyme Therapeutics in the 1st quarter valued at $52,000. Finally, First Horizon Advisors Inc. increased its stake in Halozyme Therapeutics by 24.5% in the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 293 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.